Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 6 | 6 |
| 2005 | 1 | 5 | 6 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 6 | 7 |
| 2008 | 0 | 6 | 6 |
| 2009 | 1 | 5 | 6 |
| 2010 | 2 | 13 | 15 |
| 2011 | 1 | 8 | 9 |
| 2012 | 2 | 12 | 14 |
| 2013 | 0 | 16 | 16 |
| 2014 | 2 | 22 | 24 |
| 2015 | 0 | 32 | 32 |
| 2016 | 2 | 36 | 38 |
| 2017 | 3 | 25 | 28 |
| 2018 | 2 | 32 | 34 |
| 2019 | 1 | 33 | 34 |
| 2020 | 0 | 19 | 19 |
| 2021 | 0 | 21 | 21 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 4 | 8 | 12 |
| 2025 | 0 | 17 | 17 |
| 2026 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026 Sep; 212:134-144.
-
Stabilized phospholipid-topotecan prodrug particles increase vascular permeability and ultrasound-enhanced neuroblastoma delivery. Int J Pharm. 2026 Oct 05; 703:127283.
-
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia. Mol Cancer Ther. 2026 Aug 04; 25(8):1294-1304.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models. J Exp Med. 2026 Jul 06; 223(7).
-
RLIP depletion suppresses ovarian cancer growth and metastasis. J Ovarian Res. 2026 Jan 30; 19(1).
-
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026 01 15; 147(3):276-289.
-
Identification of targetable epigenetic vulnerabilities for uveal melanoma. Cell Death Dis. 2025 Dec 12; 17(1):89.
-
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
-
Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: A novel path to cancer prevention. Int J Cancer. 2026 Apr 01; 158(7):1927-1940.